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 We assessed whether montelukast or formoterol provides additive effects to
asthmatics not controlled on inhaled corticosteroids, by studying patients who were






-receptor down regulation and subsen-










 Fifteen corticosteroid-treated, mild to moderate persistent asthmatics




g twice daily for 2 weeks,
separated by a 2-week placebo run-in and washout, in a double-blind, double-
dummy, randomized crossover design. Bronchoprotection against adenosine mono-
phosphate (AMP) challenge (primary endpoint), spirometry and blood eosinophils



















bling dilution improvements following first (1.1; 95% CI 0.4, 1.9) and last (1.0; 95%
CI 0.3, 1.8) doses of montelukast, and following first (1.3; 95% CI 0.1, 2.6) but








































140) compared with placebo, while formoterol exhibited a nonsignificant

















 In genetically susceptible patients with the homozygous glycine-16
genotype, montelukast, but not formoterol, conferred sustained anti-inflammatory
properties in addition to inhaled corticosteroid, which were dissociated from changes
in lung function after 2 weeks. Thus, assessing lung function may miss potentially
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2-agonists such as formoterol and salmeterol
are recommended as add-on therapy in asthma when
inhaled corticosteroids (ICS) provide suboptimal symp-
tom control [1, 2]. Their addition has been shown to
provide equivalent asthma control compared with using
a higher dose of ICS alone [3, 4]. However, when given










2-adrenoceptors, resulting in tolerance to their










-agonist-induced downregulation is associated with







16 and 27. At position 16, the homozygous glycine
genotype confers increased susceptibility compared with
either homozygous arginine or heterozygous genotypes
[10, 11]. Polymorphisms at position 16 are also dominant
over those at 27 in determining susceptibility. Further-





 to predispose to bronchodilator desensiti-
zation in asthmatic patients receiving regular inhaled for-
moterol [12]. Other data have suggested the homozygous
glycine-16 genotype to be associated with blunting of
the acute bronchodilator reversibility to salbutamol [13,
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14]. In contrast, in patients with the homozygous
arginine-16 genotype, the use of regular salbutamol was
associated with worse outcomes of asthma control [15,
16]. As approximately 40% of the population possess the
homozygous glycine-16 genotype [17, 18], one could
argue that this is a potentially clinically relevant determi-





Leukotriene receptor antagonists (LTRA), such as
montelukast, exhibit anti-inflammatory properties and





therapy [19]. LTRA have been shown to exhibit additive
effects to low-dose ICS [20] as well as facilitating dose
tapering in patients on high-dose ICS [21, 22]. The
objective of the present study was to evaluate, in genet-
ically susceptible patients with the glycine-16 genotype,
whether montelukast or formoterol provided additive
effects on surrogate inflammatory markers and lung func-
tion in patients suboptimally controlled on ICS.
The primary endpoint was adenosine monophosphate
(AMP) bronchial challenge, which causes bronchocon-
striction indirectly by release of inflammatory mediators
from primed airway mast cells [23]. AMP has been shown
to be more sensitive in detecting anti-inflammatory
effects of ICS than a direct bronchial challenge such as
methacholine and is probably more clinically relevant to


















[27] demonstrated in as study showing differential effects
of formoterol on AMP and histamine challenge. We also
assessed other surrogate inflammatory markers including
blood eosinophil count and nitric oxide (NO) [28, 29],
as well as spirometry and domiciliary diary cards. All
measurements were made at trough at the end of the
usual dosing interval, 12 h after last dose of formoterol
and 24 h after montelukast, when the airway would be




Fifteen nonsmoking, mild to moderate persistent asth-

























 4.7%), who had daily
symptoms despite being on inhaled corticosteroids (ICS,








1; one on fluticasone, five on
budesonide, nine on beclomethasone) and requiring at






 of rescue bronchodilator, were
recruited to completion. All patients exhibited airway
hyper-responsiveness to AMP challenge testing with a




















1) prior to the initial run-in period. All
patients had the homozygous glycine genotype at posi-
tion 16. For position 27, two patients were homozygous
for glutamine, four were homozygous for glutamic acid,
and the remaining nine were heterozygous (i.e. glutamic
acid and glutamine). In view of the small numbers of
patients with each genotype at position 27, a formal
statistical comparison was not made. Genotypes were
determined using a previously described method [12].
The study was approved by Tayside Medical Research
Ethics Committee. All patients gave written informed
consent.
In a randomized placebo-controlled, double-blind,














1; AstraZeneca Ltd, Kings Langley, UK)
plus placebo tablet once daily, or 10 mg oral montelukast
(Singulair; Merck, Sharp & Dohme Ltd, Hoddesden,
UK) once daily plus placebo Turbuhaler twice daily. Prior
to each randomized treatment as a washout period,
patients received placebo Turbuhaler and tablet for
2 weeks. Tablets were taken at 08.00 h and Turbuhalers
at 08.00 and 20.00 h. ICS dose remained stable through-
out the study. First-line rescue bronchodilator was











; Boehringer Ingelheim, Bracknell, UK),






-agonist rescue bronchodilator reserved
as second-line for use in an acute exacerbation (i.e. for
safety purposes). Patients demonstrated optimum use of
Turbuhaler at each visit. At the beginning of the trial, a
pharmacist sealed the treatments and instruction sheets in
envelopes. Compliance was assessed by tick charts and
tablet counts. Data with more than 90% overall compli-
ance were considered to be assessable; this was attained
in all cases.
Laboratory measurements including AMP, spirometry,
exhaled NO measurements and blood eosinophil counts
were performed in the morning, after placebo, and first
and last doses of randomized treatment. Rescue medica-
tion was withheld for 12 h prior to each visit. AMP
challenge testing was performed as previously described
[30]. If PC
 
















assigned. NO was measured using a LR2000 NO gas
analyser (Logan Research, Rochester, UK) as described
elsewhere [31] under standardized conditions [32].
Spirometry was performed according to American Tho-
racic Society criteria [33] using a Vitalograph Compact
spirometer (Vitalograph Ltd, Bucks, UK). Eosinophil
count was measured using an SE-9000 Haematology
analyser (Sysmex UK Ltd, Bucks, UK). Domiciliary peak
expiratory flow was measured with a Mini-Wright peak
flow meter (Clement Clarke, Essex, UK), with asthma
symptoms rated according to a four-point scale: 0 (no
symptoms) to 3 (severe symptoms), and rescue bronchod-
ilator requirements were recorded twice daily.
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The study was designed with at least 80% power to





placebo, with the alpha-error set at 0.05 (two-tailed), and





cebo) but not to compare treatments. The data for AMP
PC
 
20 were log-transformed to normalize the distribution
before analysis. Mean of the last 5 days’ domiciliary data
of each treatment period were analysed. Comparisons
between randomized treatments and placebo were made
by analysis of variance followed by multiple range testing
with Bonferroni’s correction [set at 95% confidence
interval (CI)] to obviate multiple pair-wise comparisons
(Statgraphics statistical software package; STSC Software




There were no significant carryover effects between pla-
cebo values prior to each randomized treatment after
run-in and washout for any of the measurements
(Table 1). Consequently, a pooled placebo value was used


















 0.05) doubling-dilution improve-
ments following the first (1.1; 95% CI 0.4, 1.9) and last
doses (1.0; 95% CI 0.3, 1.8) of montelukast (Figure 1,
Table 2). Formoterol showed significant improvement
after the first (1.3; 95% CI 0.1, 2.6) but not after the last




0.9, 1.6). The individual data for
AMP responses showed no differences between the gen-
otypes at position 27, with most individuals exhibiting
loss of protection between the first and last doses of
formoterol (data not shown). After 2 weeks, montelukast





























-140) compared with placebo, while there was a non-
significant increase after 2 weeks of formoterol (20; 95%
CI -92, 132) (Figure 2). There were no significant effects
on NO for montelukast or formoterol compared with
placebo after 2 weeks (Figure 2).
Laboratory lung function
There were significant improvements after the first dose
of formoterol compared with placebo for FEF25-75 and
PEF, but not for FEV1 (Figure 3). No significant differ-
ences were found between placebo vs. the last dose of
formoterol, or vs. the first or last dose of montelukast for
any lung function parameters (Table 2).
Domiciliary diary cards
Compared with placebo, both treatments showed signif-
icant (P < 0.05) improvements in daytime rescue use (i.e.
recorded pm) but not for any other endpoints (Table 3).






AMP PC20 (mg ml-1) 34.1 [1.31] 39.1 [1.25]
NO (p.p.b) 11.9 [8.75–15.1] 14.6 [11.4–17.8]
EOS (¥ 106 l-1) 338 [276–400] 327 [265–389]
FEV1 (l) 2.55 [2.34–2.75] 2.45 [2.25–2.65]
FEF25-75 (l s-1) 1.81 [1.59–2.02] 1.90 [1.69–2.12]
PEF [lab] (l min-1) 398 [371–424] 396 [370–423]
PEFam (l min-1) 385 [370–395] 395 [385–405]
PEFpm (l min-1) 410 [400–420] 415 [405–425]
RESam (puffs 12 h-1) 3.6 [3.0–4.2] 4.0 [3.4–4.6]
RESpm (puffs 12 h-1) 4.4 [3.6–5.2] 4.4 [3.6–5.2]
SYMam (U 12 h-1) 0.8 [0.7–1.0] 0.8 [0.7–0.9]
SYMpm (U 12 h-1) 0.9 [0.8–1.0] 0.8 [0.6–0.9]
Means [95% confidence intervals] adenosine monophosphate PC20
(AMP PC20), exhaled nitric oxide (NO), blood eosinophil count
(EOS), forced expiratory volume in 1 second (FEV1), forced mid
expiratory flow (FEF25-75), laboratory peak expiratory flow (PEFlab),
domiciliary morning/evening peak expiratory flow (PEFam/pm), day-
time/night-time symptom score (SYMam/pm) and daytime/night-
time rescue bronchodilator requirement (RESam/pm).There were no
significant differences for any endpoints.
Figure 1 Change from pooled placebo in the primary outcome 
(AMP PC20). *P < 0.05 vs. placebo. First dose (); second dose 
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Table 2 Means [95% confidence limits] for laboratory and domiciliary diary card data for pooled placebo and each randomized treatment.
Pooled placebo
Montelukast
First dose Last dose
Formoterol 
First dose Last dose
AMP PC20 (mg ml-1) 36.3 [27.5–49.0] 79.4* [58.9–104.7] 74.6* [55.9–99.5] 91.2* [56.2–151.4] 45.7 [28.2–75.9]
NO (p.p.b) 13.3 [9.7–16.8] 12.9 [9.3–16.4] 8.83 [5.3–12.4] 13.6 [11.3–15.8] 11.3 [9.0–13.5]
EOS (¥ 106 l-1) 333 [294–372] 312 [271–353] 261* [222–300] 327 [263–390] 353 [289–416]
FEV1 (l) 2.50 [2.35–2.65] 2.51 [2.38–2.63] 2.47 [2.35–2.60] 2.67 [2.52–2.82] 2.43 [2.28–2.58]
FEF25-75 (l s-1) 1.85 [1.71–2.00] 1.92 [1.78–2.07] 1.91 [1.76–2.05] 2.23* [2.05–2.40] 1.95 [1.78–2.12]
PEF [lab] (l min-1) 395 [380–415] 400 [380–420] 410 [390–425] 430* [415–450] 410 [390–42]
Means [95% confidence intervals] adenosine monophosphate PC20 (AMP PC20), exhaled nitric oxide (NO), blood eosinophil count (EOS), forced
expiratory volume in 1 second (FEV1), forced mid expiratory flow (FEF25-75)), laboratory peak expiratory flow (PEFlab), domiciliary morning/
evening peak expiratory flow (PEFam/pm), daytime/night-time symptom score (SYMam/pm) and daytime/night-time rescue bronchodilator
requirement (RESam/pm). *Denotes a significant difference between pooled placebo and randomized treatments.
Figure 2 Change from pooled placebo in FEV1 and FEF25-75. 

















































10 mg qd Figure 3 Change from pooled placebo in blood eosinophils and 
exhaled nitric oxide. *P < 0.05 vs. placebo. (The change in exhaled 
nitric oxide with montelukast was not significantly different vs. 
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endogenous catecholamines in their basal state and there-
fore more prone to subsequent exogenous downregula-
tion. According to the static baseline model, where
effects of endogenous catecholamines are less important
on pretrial b2-receptor regulation, the converse would be
expected in terms of exogenous b2-agonists promoting
further downregulation in the glycine-16 genotype but
not in the arginine-16 genotype, in response to exoge-
nous b2-agonist therapy. Further large-scale prospective
clinical trials with different genotypes at 16 and 27 are
required to resolve which baseline model is more impor-
tant in determining the development of tolerance with
long-acting b2-agonists.
Previous in vitro and in vivo studies have shown that
the susceptibility to tolerance conferred by the glycine-
16 genotype overcomes any resistance conferred by the
glutamic acid-27 genotype for patients who exhibit this
haplotype in combination. However, the situation is
potentially even more complex when taking into account
all of the different haplotypes with multiple single-
nucleotide polymorphisms. We were unable to determine
these complex haplotypes because our database is only
characterized according to polymorphisms at position 16
and 27.
It was shown in a retrospective analysis by Drysdale
et al. [40] that these unique interactions of multiple poly-
morphisms within a haplotype may determine the acute
bronchodilator response to a single dose of salbutamol.
Further pharmacogenetic studies are required to prospec-
tively evaluate whether such haplotypes determine the
development of tolerance with chronic dosing of long-
acting b2-agonists for functional antagonism against
bronchoconstriction. Indeed, our data revealed marked
tolerance following formoterol, which would vindicate
the selection of patients with the glycine-16 genotype.
Our sample size precluded formal statistical compari-
son of the different genotypes at position 27, but we did
not observe any obvious trends from inspection of indi-
Pooled placebo Montelukast Formoterol
PEFam (l min-1) 390 [375–400] 400 [390–415] 405 [390–415]
PEFpm (l min-1) 410 [400–425] 420 [410–430] 420 [400–425]
RESam (puffs 12 h-1) 3.6 [1.2–4.8] 2.4 [1.2–3.6] 2.4 [1.2–3.6]
RESpm (puffs 12 h-1) 4.4 [3.6–5.4] 2.6* [1.8–3.6] 2.8* [2.0–3.8]
SYMam (U 12 h-1) 0.8 [0.6–1.0] 0.7 [0.5–0.9] 0.8 [0.6–0.9]
SYMpm (U 12 h-1) 0.8 [0.6–1.0] 0.7 [0.5–0.9] 0.8 [0.6–0.9]
Means [95% confidence intervals] adenosine monophosphate PC20 (AMP PC20), exhaled nitric
oxide (NO), blood eosinophil count (EOS), forced expiratory volume in 1 second (FEV1),
forced mid expiratory flow (FEF25-75), laboratory peak expiratory flow (PEFlab), domiciliary
morning/evening peak expiratory flow (PEFam/pm), daytime/night-time symptom score
(SYMam/pm) and daytime/night-time rescue bronchodilator requirement (RESam/pm).
*Denotes a significant difference between pooled placebo and randomized treatments.
Table 3 Means (95% confidence limits) 
for domiciliary diary card data for pooled 
placebo and each randomized treatment.
Discussion
The results of the present study showed sustained bron-
choprotection against AMP challenge with montelukast
but not formoterol in addition to ICS in genetically
susceptible patients who would be expected to fare worse
with a long-acting b2-agonist. This observation is in
keeping with studies using indirect challenges in non-
genotyped patients, as reported by Wilson et al. [34] with
AMP in steroid-treated patients, and by Villaran et al. [35]
and Edelman et al. [36] with exercise in mostly steroid-
naive patients, where comparisons were made between
salmeterol and montelukast. However using the direct
stimulus of methacholine challenge in steroid-treated
patients with the homozygous glycine-16 genotype, for-
moterol 9 mg b.i.d. and zafirlukast 20 mg b.i.d. both
exhibited significant residual trough protection after
1 week [37]. The degree of formoterol-induced tolerance
for methacholine protection may not be influenced by
polymorphisms at position 16 or 27. This is perhaps not
surprising given that tolerance to bronchoprotective
effects of b2-agonists is more pronounced for indirect
than direct stimuli [38].
In order to fully understand the pharmacogenetics of
b2-receptor regulation, it is important to consider the
potential role of endogenous catecholamines in the basal
state. In vitro data from transfected cell lines has shown
that the glycine-16 genotype is more susceptible to b2-
agonist-induced downregulation than the arginine-16
genotype. According to Liggett, the dynamic baseline
model would result in patients with the glycine-16 gen-
otype being susceptible to pretrial downregulation by
endogenous catecholamines, such that their receptors
would already be downregulated in the basal state, and
therefore less prone to further downregulation by subse-
quent exogenous b2-agonist therapy [39]. In contrast, the
arginine-16 genotype, according to the dynamic model,
would be relatively resistant to the pretrial effects of
Add-on therapy with montelukast or formoterol.
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vidual data (not shown). It is important to point out that
there is linkage disequilibrium, with the haplotype com-
bination of homozygous glutamic acid at position 27
always being associated with homozygous glycine at posi-
tion 16, although the homozygous glycine-16 genotype
may occur in combination with any other genotype at
position 27.
The degree of tolerance between the first and last dose
protection against AMP challenge shown here for for-
moterol (a 1.0 doubling-dilution trough difference) con-
curs with previous data reported by Wilson et al. [34] for
salmeterol (1.2 doubling-dilution trough difference) and
with Aziz et al. [5] for formoterol (1.9 doubling-dilution
peak difference) in nongenotyped patients, the latter
receiving 18 mg twice daily, as opposed to 9 mg twice
daily used here. This in turn would suggest that the
bronchoprotective tolerance occurs irrespective of the
position-16 genotype for AMP challenge.
The addition of montelukast, but not formoterol, sig-
nificantly reduced peripheral blood eosinophils but did
not significantly reduce exhaled nitric oxide, although
the latter showed a trend. A similar additive reduction of
blood eosinophils with montelukast has been reported by
Wilson et al. and Laviolette et al. [20]. Furthermore,
while Wilson et al. showed no additive effects of mon-
telukast on exhaled NO [34], in another study zafirlukast
as add-on therapy exhibited a small but significant effect
[37]. Montelukast as monotherapy has also been shown
to suppress NO [29, 41]. In this respect, it is recognized
that low-dose ICS exhibit a maximal suppression of
exhaled nitric oxide to near-normal values [25]. In addi-
tion, Tamaoki et al. showed that adding pranlukast, com-
pared with placebo, facilitated a halving of the dose of
ICS without any increase in levels of NO or serum
eosinophilic cationic protein [21].
In terms of laboratory lung function, neither treatment
afforded significant improvements in FEV1 at either dose,
although a significant increase in FEF25-75 and PEF was
only shown after first-dose formoterol. For domiciliary
measurements, no significant improvement in morning
or evening domiciliary PEF or symptoms were found
with montelukast or formoterol. Improvements in labo-
ratory and domiciliary pulmonary function have been
reported as add-on therapy in comparative studies with
salmeterol, formoterol, montelukast or zafirlukast [34, 37,
41–43].
The effects on lung function are always biased towards
a bronchodilator such as a long-acting b2-agonist, espe-
cially when patients are selected according to salbutamol
reversibility as an inclusion criteria [42–44]. Our patients
were not selected on the basis of bronchodilator revers-
ibility. Nonetheless, the significant improvements in PEF
and FEF25-75 after the first dose of formoterol were not
sustained after 2 weeks, in keeping with their genetic
susceptibility to developing bronchodilator tolerance
[12]. However, it is possible that we have missed a small
but sustained improvement in lung function, as our study
was not powered on this endpoint.
The lack of any additional improvement with mon-
telukast on domiciliary or laboratory PEF in our study
is similar to that described by Robinson et al. [45] in
more severe patients, although their patients were already
on maximal therapy and they did not evaluate any
inflammatory endpoints. Our data showing additive sig-
nificant effects on AMP and eosinophils with mon-
telukast emphasize the point that assessing lung function
only will miss potentially beneficial anti-inflammatory
effects of leukotriene receptor antagonists.
In summary, we have shown that in patients genetically
predisposed to b2-adrenoceptor desensitization with the
glycine-16 genotype, montelukast, but not formoterol,
exhibited sustained anti-inflammatory properties addi-
tional to inhaled corticosteroid in terms of bronchopro-
tection and reduction of blood eosinophils, which were
dissociated from any changes in lung function after
2 weeks. Montelukast may therefore be a suitable alter-
native to a long-acting b2-agonist in patients who are
predisposed to tolerance. Moreover, assessing lung func-
tion may miss potential anti-inflammatory benefits of
montelukast when used as add-on therapy.
The authors wish to acknowledge Professor Ian Hall from the
University of Nottingham for performing the b2-adrenoceptor
genotype assays. The study was supported by an unrestricted edu-
cational grant from Merck Inc, USA.
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